OVERVIEW OF VACCINATION STATUS AND COMORBIDITIES IN DEATHS DUE TO COVID-19 OMICRON VARIANT IN RIAU PROVINCE, 2022
Gambaran Status Vaksinasi dan Komorbiditas pada Pasien Meninggal Akibat COVID-19 Varian Omicron di Provinsi Riau, 2022
Downloads
Background: The Corona Virus Disease 2019 (COVID-19) pandemic is causing problems in public health. One of the prevention efforts is vaccination. Omicron, the new variant of COVID-19, is a variant that is spreading rapidly in Indonesia, including in Riau Province. Purpose: This study aims to describe the determinants of vaccination status in deaths of Omicron variant COVID-19 patients in Riau Province from February to April 2022. Methods: Cross-sectional research was conducted using secondary data. A total of 158 patients who died with confirmed COVID-19 and the Omicron variant via S-Gene Target Failure (SGTF) and sequencing test, and were treated at a referral hospital in Riau Province within two months (8 February – 4 April 2022) were included in the study. The distribution of patient deaths was analyzed univariately and bivariately. Results: Most of the death cases were unvaccinated (67.09%). As many as 48.73% of the 158 deaths were elderly ≥61 years, and the majority (70.13%) of cases were unvaccinated. It was found that 64.56% of the 158 patient deaths occurred in mainland Riau, and the majority (67.65%) were unvaccinated. Diabetes mellitus (35.86%) and cardiovascular disease (28.97%) were the highest comorbidities. Conclusion: In preventing deaths due to COVID-19, it is necessary to accelerate and increase vaccination coverage, especially for children and the elderly in land and coastal areas. Vaccination can optimize protection against COVID-19. Apart from that, efforts are needed to prevent the severity of comorbidities.
Meo A, Al-Jassir F, Klonoff D. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;24(25):8012–8.
WHO South East Asia. Technical Brief: Enhancing Readiness for Omicron in the WHO Asia Region. 2021.
Callaway E, Ledford H. How bad is Omicron? What scientists know so far. Nature. 2021;600(7888):197–9.
Kadir A, Deby S, Sunarno AM. A systematic review of Omicron outbreak in Indonesia: a case record and how the country is weathering the new variant of COVID-19. European Journal of Molecular & Clinical Medicine. 2022;9(1):364–73.
Satuan Tugas Penanganan COVID 19. Peta Sebaran COVID-19 [Internet]. 2022 [cited 2022 Feb 28].
Sukirman R, Mulyanto I, Malfasari E, Mahkota R. Epidemiological characteristics of COVID-19 in 2020-2021: cross-sectional study in Riau Province. Jurnal Epidemiologi Kesehatan Indonesia. 2022;6(1):37–44.
Mohiuddin M, Kasahara K. Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options. Respir Med. 2022 Jan 1;191.
Jamil K, Winardi W, Yufika A, Anwar S, Librianty N, Prashanti N, et al. Knowledge of coronavirus disease 2019 (COVID-19) among healthcare providers: A cross-sectional study in Indonesia. Asian Pac J Trop Med. 2020 Sep 1;13(9):402–8.
Kaunang ED, Kristanto EG, Panelewen J, Rotty IE. Clinical characteristics of COVID-19 deaths: an electronic medical records-based study. Open Access Maced J Med Sci. 2022;10(B):2509–12.
Jassat W, Abdool Karim SS, Mudara C, Welch R, Ozougwu L, Groome MJ, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Glob Health [Internet]. 2022 Jul 1;10(7): e961–9.
Ward IL, Bermingham C, Ayoubkhani D, Gethings OJ, Pouwels KB, Yates T, et al. Risk of COVID-19-related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022;378.
Longo D, Fauci A, Kasper D, Hauser S. Principles of internal medicine. 18th ed. New York: McGraw-Hill; 2020.
Rabaan AA, Tirupathi R, Sule AA, Aldali J, Mutair A Al, Alhumaid S, et al. Viral dynamics and real-time rt-pcr ct values correlation with disease severity in COVID-19. Diagnostics (Basel). 2021 Jun;11(6).
Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Estimated effectiveness of covid-19 vaccines against omicron or delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5(9): e2232760–e2232760.
Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection against the Omicron variant from previous SARS-CoV-2 infection. New England Journal of Medicine. 2022;386(13):1288–90.
Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age, and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022 Mar;27(9).
Peralta-Santos A, Rodrigues EF, Moreno J, Ricoca V, Casaca P, Fernandes E, et al. Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2). SSRN Electronic Journal. 2022;1–12.
Martins-Filho PR, de Souza Araújo AA, Quintans-Júnior LJ, Soares BDS, Barboza W de S, Cavalcante TF, et al. Dynamics of hospitalizations and in-hospital deaths from COVID-19 in northeast Brazil: a retrospective analysis based on the circulation of SARS-CoV-2 variants and vaccination coverage. Epidemiol Health. 2022;44: e2022036.
Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, B Pearson CA, et al. COVID-19 length of hospital stays: a systematic review and data synthesis. BMC Med. 2020 Sep;18(1):270.
Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, et al. Diagnostic SARS-CoV-2 cycle threshold value predicts disease severity, survival, and six-month sequelae in COVID-19 Symptomatic Patients. Viruses. 2021 Feb;13(2).
Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalization and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet. 2022;399(10332):1303–12.
Ribeiro Xavier C, Sachetto Oliveira R, da Fonseca Vieira V, Lobosco M, Weber Dos Santos R. Characterisation of Omicron variant during covid-19 pandemic and the impact of vaccination, transmission rate, mortality, and reinfection in South Africa, Germany, and Brazil. Biotech (Basel (Switzerland)). 2022 Apr;11(2).
Yu H, Yang J. Projecting the impact of the introduction of SARS-CoV-2 Omicron variant in China in the context of waning immunity after vaccination. Nature Portfolio. 2022;1–12.
Roziqoh Y, Syafriadi M, Sugianta. Forecasting of COVID-19 with Autoregressive Integrated Moving Average (ARIMA) method in East Java Province. Jurnal Berkala Epidemiologi. 2023;11(2):160–9.
Budiman D. Analisis melacak sebaran dan penyebab tingginya kematian COVID-19 di Indonesia [Internet]. 2022 [cited 2022 Jul 16].
Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020 Jul;30(8):1236–48.
Gunadi, Hakim MS, Wibawa H, Vujira KA, Puspitarani DA, Supriyati E, et al. Comparative analysis of the outcomes of COVID-19 between patients infected with SARS-CoV-2 Omicron and Delta variants: a retrospective cohort study. medRxiv. 2022;
Suryaputra GP, Apriningsih H, Wardani MM. Relationship between comorbidities and mortality and length of stay in COVID-19 patients at UNS Surakarta Hospital. Plexus Medical Journal. 2022;1(1):32–41.
- Every manuscript submitted to must observe the policy and terms set by the Jurnal Berkala Epidemiologi
- Publication rights to manuscript content published by the Jurnal Berkala Epidemiologi is owned by the journal with the consent and approval of the author(s) concerned. (download copyright agreement)
- Complete texts of electronically published manuscripts can be accessed free of charge if used for educational and research purposes according to copyright regulations.
JBE by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
